Motorola Solutions Announces Increase in Aggregate Purchase Price of Tender Offers for Certain of its Outstanding Debt
![](https://i1.wp.com/picante.today/wp-content/uploads/2019/05/MSI-Vertical-1.jpg?fit=150%2C150&ssl=1)
CHICAGO–(BUSINESS WIRE)–Motorola Solutions, Inc. (NYSE: MSI) (the “Company”) announced today
that it has increased the aggregate purchase price of its debt tender
offers to purchase for cash (i) any and all of the Company’s outstanding
securities listed in Table I below (the “Any and All Notes”) (such
offer, the “Any and All Offer”), and (ii) up to the Maximum Waterfall
Tender Amount (as defined below) in aggregate purchase price of the
Company’s outstanding securities listed in Table II below (collectively,
the “Waterfall Notes” and, together with the Any and All Notes, the
“Securities”), subject to the Acceptance Priority Levels as defined
below (such offer, the “Waterfall Offer”).
The “Maximum Waterfall Tender Amount” has been increased from (i) an
aggregate purchase price equal to $500 million less the aggregate
purchase price of the Any and All Notes validly tendered and accepted
for purchase in the Any and All Offer to (ii) an aggregate purchase
price equal to $650 million less the aggregate purchase price of
the Any and All Notes validly tendered and accepted for purchase in the
Any and All Offer. All other terms of tender offers remain unchanged.
The tender offers are intended to allow the Company to issue new debt
securities to fund the repurchase of the Securities, thereby extending
the maturity date of its near-term debt securities and reducing the
amounts outstanding under the higher-cost portion of its debt security
portfolio. The Company expects to fund the tender offers with the
proceeds from the issuance and sale of debt securities in one or more
capital markets transactions, together with available cash on hand.
Table I |
||||||||||||||||||
Securities Subject to the Any and All |
||||||||||||||||||
Principal | Early | Reference U.S. | Bloomberg |
|
||||||||||||||
Title of | Amount | Tender | Treasury | Reference |
Fixed Spread |
|||||||||||||
Security | Outstanding | CUSIP/ISIN |
Premium(1) |
Security | Page/Screen |
(basis points) |
||||||||||||
7.500% Senior Notes due 2025 | $346,930,000 |
CUSIP: 620076 AH2 ISIN:US620076AH21 |
$50.00 | 2.250% U.S.T. due 04/30/24 | PX1 | 165 | ||||||||||||
6.500% Senior Notes due 2025 | $117,892,000 |
CUSIP: 620076 AK5
ISIN: US620076AK59 |
$50.00 | 2.250% U.S.T. due 04/30/24 | PX1 | 170 | ||||||||||||
6.500% Senior Notes due 2028 | $36,463,000 |
CUSIP: 620076 AP4
ISIN: US620076AP47 |
$50.00 | 2.625% U.S.T. due 02/15/29 | PX1 | 195 | ||||||||||||
6.625% Senior Notes due 2037 | $54,533,000 |
CUSIP: 620076 BA6 ISIN: US620076BA68 |
$50.00 | 3.000% U.S.T. due 02/15/49 | PX1 | 285 |
(1) |
The total consideration payable for each $1,000 principal amount of Securities validly tendered at or prior to the Early Tender Deadline and accepted for purchase by us includes the applicable Early Tender Premium. In addition, holders whose Securities are accepted will also receive accrued interest on such Securities. |
|
Table II |
|||||||||||||||||||||
Securities Subject to the Waterfall Offer |
|||||||||||||||||||||
|
|||||||||||||||||||||
Principal |
Acceptance |
Bloomberg | |||||||||||||||||||
Title of | Amount |
Priority |
Early Tender | Reference US Treasury | Reference | Fixed Spread | |||||||||||||||
Security | Outstanding | CUSIP/ISIN | Level |
Premium(1) |
Security | Page/Screen |
(basis points) |
||||||||||||||
3.500% Senior Notes due 2021 | $400,000,000 |
CUSIP: 620076 BD0
ISIN: US620076BD08 |
1 | $50.00 | 2.250% U.S.T. due 04/30/21 | PX1 | 50 | ||||||||||||||
3.750% Senior Notes due 2022 | $750,000,000 |
CUSIP: 620076 BB4
ISIN: US620076BB42 |
2 | $50.00 | 2.250% U.S.T. due 04/15/22 | PX1 | 50 | ||||||||||||||
3.500% Senior Notes due 2023 | $600,000,000 |
CUSIP: 620076 BC2
ISIN: US620076BC25 |
3 | $50.00 | 2.250% U.S.T. due 04/30/24 | PX1 | 80 |
(1) |
The total consideration payable for each $1,000 principal amount of Securities validly tendered at or prior to the Early Tender Deadline and accepted for purchase by us includes the applicable Early Tender Premium. In addition, holders whose Securities are accepted will also receive accrued interest on such Securities. |
|
Subject to the Maximum Waterfall Tender Amount, the amounts of each
series of Waterfall Notes that are purchased in the Waterfall Offer will
be determined in accordance with the acceptance priority levels
specified in Table II above (the “Acceptance Priority Levels”), with 1
being the highest Acceptance Priority Level and 3 being the lowest
Acceptance Priority Level.
The tender offers are being made pursuant to, and are subject to the
satisfaction or waiver of the terms and conditions, including a
financing condition relating to the receipt of net proceeds from the
completion of our issuance and sale of debt securities in one or more
capital markets transactions, set forth in the Offer to Purchase, dated
May 9, 2019, and the related Letter of Transmittal (as they may each be
amended or supplemented from time to time, the “Offer Documents”). The
tender offers will expire at midnight, New York City time, at the end of
June 6, 2019, unless extended or terminated (the “Expiration Date”).
Tenders of Securities may be properly withdrawn at any time at or prior
to 5:00 p.m., New York City time, on May 22, 2019, but may not be
properly withdrawn thereafter, except where additional withdrawal rights
are required by law.
Holders of Securities that are validly tendered and not properly
withdrawn at or prior to 5:00 p.m., New York City time, on May 22, 2019
(unless extended, the “Early Tender Deadline”) and accepted for purchase
will receive the applicable “Total Consideration,” which includes the
applicable early tender premium specified in the applicable table above
(the “Early Tender Premium”). Payment for Securities that are validly
tendered and not properly withdrawn at or prior to the Early Tender
Deadline and accepted for purchase will be made as soon as reasonably
practicable following the Early Tender Deadline (such date with respect
to the applicable Offer, the “Early Settlement Date”). The Company
expects that the Early Settlement Date will be May 24, 2019, the first
business day after the Price Determination Date. Holders of Securities
who validly tender their Securities following the Early Tender Deadline
and at or prior to the Expiration Date will only receive the applicable
“Tender Offer Consideration” for Securities accepted for purchase, which
is equal to the applicable Total Consideration minus the applicable
Early Tender Premium.
The prices to be paid for each series of Securities subject to the
tender offers and accepted for purchase will be determined at 11:00
a.m., New York City time, on the first business day following the Early
Tender Deadline (as it may be extended with respect to the applicable
offer, the “Price Determination Date”). Promptly after 11:00 a.m., New
York City time, on the Price Determination Date, the Company will issue
a press release specifying, among other things, the Total Consideration
for each series of Securities and the aggregate principal amount of
Securities validly tendered at or prior to the applicable Early Tender
Deadline and accepted for purchase.
Payments for Securities purchased will include accrued and unpaid
interest from and including the last interest payment date applicable to
the relevant series of Securities up to, but not including, the
applicable settlement date for such Securities accepted for purchase.
If the Waterfall Offer is not fully subscribed as of the Early Tender
Deadline, subject to the Maximum Waterfall Tender Amount, Waterfall
Notes validly tendered and not properly withdrawn at or prior to the
Early Tender Deadline will be accepted for purchase in priority to other
Waterfall Notes tendered following the Early Tender Deadline, even if
such Waterfall Notes tendered following the Early Tender Deadline have a
higher Acceptance Priority Level than Waterfall Notes tendered at or
prior to the Early Tender Deadline.
Waterfall Notes of a series may be subject to proration if the aggregate
purchase price of the Waterfall Notes of such series validly tendered
and not properly withdrawn would cause the Maximum Waterfall Tender
Amount to be exceeded. Furthermore, if the Waterfall Offer is fully
subscribed as of the Early Tender Deadline, holders who validly tender
Waterfall Notes following the Early Tender Deadline will not have any of
their Waterfall Notes accepted for purchase.
The Company’s obligation to accept for payment and to pay for the
Securities validly tendered in the tender offers is subject to the
satisfaction or waiver of the conditions, including a financing
condition relating to the receipt of net proceeds from the completion of
our issuance and sale of debt securities in one or more capital markets
transactions, described in the Offer to Purchase.
The company also announced today that it has retained Santander, TD
Securities and US Bancorp to serve as the Co-Dealer Managers in
connection with the tender offers. BofA Merrill Lynch and Mizuho
Securities are serving as the Lead Dealer Managers in connection with
the tender offers. The information agent and tender agent is Global
Bondholder Services Corporation. The full details of the tender offers,
including complete instructions on how to tender Securities, are
included in the Offer Documents. Holders are strongly encouraged to read
carefully the Offer Documents, including materials incorporated by
reference therein, because they will contain important information.
Copies of the Offer Documents and related offering materials are
available by contacting the information agent at (212) 430-3774 (banks
and brokers) or (866) 807-2200 (all others). Questions regarding the
tender offers should be directed to the Lead Dealer Managers, BofA
Merrill Lynch, at (980) 387-3907 or (888) 292-0070 (toll free) or Mizuho
Securities, at (212) 205-7736 or (866) 271-7403 (toll free).
None of the Company or its affiliates, their respective boards of
directors, the dealer managers, the information agent and tender agent
or the trustee with respect to any Securities is making any
recommendation as to whether holders should tender any Securities in
response to the tender offers, and neither the Company nor any such
other person has authorized any person to make any such recommendation.
Holders must make their own decision as to whether to tender any of
their Securities, and, if so, the principal amount of Securities to
tender.
This news release shall not constitute an offer to sell, a solicitation
to buy or an offer to purchase or sell any securities. The tender offers
are being made only pursuant to the Offer to Purchase and only in such
jurisdictions as is permitted under applicable law.
About Motorola Solutions, Inc.
Motorola Solutions is a global leader in mission-critical
communications. Our technology platforms in communications, command
center software, services and video security and analytics make cities
safer and help communities and businesses thrive. At Motorola Solutions,
we are ushering in a new era in public safety and security. Learn more
at www.motorolasolutions.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains statements that constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 and other federal securities laws. These
“forward-looking statements” are statements other than statements of
historical fact and may include, among other things, statements in
relation to the Company’s current expectations and beliefs as to its
ability to consummate the tender offers and redemption, including the
timing, size, pricing or other terms of the tender offers, and other
future events. All information set forth in this release is as of the
date hereof. The Company does not intend, and undertakes no duty, to
update this information to reflect future events or circumstances.
Actual results are subject to a number of risks and uncertainties and
may differ materially from the current expectations and beliefs
discussed in this press release. Certain potential factors, risks and
uncertainties that could affect the Company’s business and financial
results and cause actual results to differ materially from those
expressed or implied in any forward-looking statements include the
Company’s ability to complete the tender offers and satisfy the
conditions thereto, and other potential factors, risks and uncertainties
under the heading “Risk Factors” in its Annual Report on Form 10-K for
the year ended December 31, 2018, which is on file with the Securities
and Exchange Commission (“SEC”) and available at the SEC’s website at www.sec.gov.
MOTOROLA, MOTOROLA SOLUTIONS and the Stylized M Logo are trademarks
or registered trademarks of Motorola Trademark Holdings, LLC and are
used under license. All other trademarks are the property of their
respective owners. ©2019 Motorola Solutions, Inc. All rights reserved.
Contacts
Investor Contact:
Chris Kutsor
Motorola Solutions
+1
847-576-4995
[email protected]
Media Contact:
Kate Dyer
Motorola Solutions
+224-374-3124
[email protected]
![](https://grassnews.net/wp-content/uploads/2019/03/Grassnews-600px.png)
Indivior
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
- Primary and Secondary End Points of the Study were Not Met
- Indivior Does Not Currently Expect to Exercise AEF0117 Option
SLOUGH, United Kingdom and RICHMOND, Va., Sept. 4, 2024 /PRNewswire/ — Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma’s announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The purpose of this trial was twofold: (1) to show that AEF0117 (0.1, 0.3, 1 mg once a day for 12 weeks) lowers cannabis use and (2) to determine the endpoints and optimal dosage of AEF0117 for use in future studies. In this phase 2B study, patients were treatment-seeking participants, 84% of whom had severe CUD.
The results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to ≤1 day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used ≤2 day per week, were not met. Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD.
This clinical Phase 2B study is part of the strategic collaboration between Aelis Farma and Indivior, which includes an exclusive option for Indivior to license the global rights to AEF0117. Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favorable clinical data, Indivior does not currently expect to exercise its option.
Important Cautionary Note Regarding Forward-Looking Statements
This news release contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding whether: we will be able to ultimately demonstrate the safety and efficacy of AEF0117, which is a prerequisite to filing any New Drug Application; we might ever exercise our option for AEF0117 and, if so, when; and other statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” “outlook,” “guidance,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.
Actual results may differ materially from those because they relate to future events. Various factors may cause differences between Indivior’s expectations and actual results, including, among others, the risks described in our most recent annual report on Form 20-F beginning on page 9 as filed with the U.S. SEC and in subsequent releases; legal and market restrictions that may limit how quickly we can repurchaser our shares; the substantial litigation and ongoing investigations to which we are or may become a party; our reliance on third parties to manufacture commercial supplies of most of our products, conduct our clinical trials and at times to collaborate on products in our pipeline; our ability to comply with legal and regulatory settlements, healthcare laws and regulations, requirements imposed by regulatory agencies and payment and reporting obligations under government pricing programs; risks related to the manufacture and distribution of our products, most of which contain controlled substances; market acceptance of our products as well as our ability to commercialize our products and compete with other market participants; competition; the uncertainties related to the development of new products, including through acquisitions, and the related regulatory approval process; our dependence on third-party payors for the reimbursement of our products and the increasing focus on pricing and competition in our industry; unintended side effects caused by the clinical study or commercial use of our products; our ability to successfully execute acquisitions, partnerships, joint ventures, dispositions or other strategic acquisitions; our ability to protect our intellectual property rights and the substantial cost of litigation or other proceedings related to intellectual property rights; the risks related to product liability claims or product recalls; the significant amount of laws and regulations that we are subject to, including due to the international nature of our business; macroeconomic trends and other global developments such as armed conflicts and pandemics; the terms of our debt instruments, changes in our credit ratings and our ability to service our indebtedness and other obligations as they come due; changes in applicable tax rate or tax rules, regulations or interpretations and our ability to realize our deferred tax assets; and volatility in our share price due to factors unrelated to our operating performance or that may result from the potential move of our primary listing to the U.S.
Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.
This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
References:
- National Library of Medicine (U.S.) (2022, April). Effect of AEF0117 on treatment-seeking patients with cannabis use disorder (CUD) (SICA2). Identifier
NCT05322941 https://www.clinicaltrials.gov/study/NCT05322941
Logo – https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/indivior-provides-update-on-aelis-farmas-clinical-phase-2b-study-results-with-aef0117-in-participants-with-cannabis-use-disorder-302237355.html
Innocan
Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options
![innocan-pharma-announces-closing-of-private-placement-and-grant-of-stock-options](https://grassnews.net/wp-content/uploads/2024/08/61828-innocan-pharma-announces-closing-of-private-placement-and-grant-of-stock-options.jpg)
HERZLIYA, Israel and CALGARY, Alberta, Aug. 29, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has completed its previously announced non-brokered private placement offering of 5,025,725 units of the Company (the “Units”) at a price of C$0.22 per Unit for gross proceeds of C$1,105,659.50 (the “Offering”).
Each Unit is comprised of: (i) one (1) common share in the capital of the Company (each a “Common Share”); and (ii) one (1) common share purchase warrant (each a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of C$0.32 for a period of four (4) years from the date of issuance.
Innocan intends to use the proceeds of the Offering for working capital and general corporate purposes.
The securities issued to Canadian subscribers in connection with the Offering are subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.
Iris Bincovich, Chief Executive Officer of the Company, stated “we are very pleased with our successful offering. I would like to extend my sincere gratitude to our investors for their unwavering support. We see this as a strong vote of confidence by both existing and new investors which demonstrates investor support of our vision and strategic direction. These new funds will provide us with additional working capital to enable us to capitalize on new opportunities and allow us to advance strongly on our growth plans.”
The Company is also pleased to announce that it has granted an aggregate of 300,000 stock options (each an “Option“) to certain consultants of the Company pursuant to the Company’s stock option plan (the “Plan“). Each Option may be exercised for one (1) common share in the capital of the Company (each, a “Share“) at a price of $0.25 per Share. The Options expire on August 27, 2029.
All Options granted vest in accordance with the following vesting schedule: (i) 1/3rd of the Options vested immediately at grant; (ii) 1/3rd of the Options will vest on February 28, 2025; and (iii) 1/3rd will vest on August 27, 2025; all subject to the terms and conditions of the Plan.
About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Logo – https://mma.prnewswire.com/media/2046271/4883982/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-closing-of-private-placement-and-grant-of-stock-options-302234455.html
Cannabis
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
![](https://grassnews.net/wp-content/uploads/2024/08/europe-medical-cannabis-market-forecast-2024-2032-tilray-aurora-cannabis-and-gw-pharmaceuticals-dominate-the-market-landscape.gif)
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.
The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:
- Derivatives;
- Source;
- Application;
- Route of Administration;
- End-user;
- Distribution Channel; and
- Country.
Market Highlights Identified in the Report
- Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
- Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
- Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.
The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.
Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.
Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.
Regional Insights
Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.
Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.
Competitive Landscape
The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.
The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.
Key Topics Covered
Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurora Cannabis Inc.
- Bedrocan
- Biocann
- BIOTA Biosciences LLC
- Cannamedical
- Mary Jane CBD
- Sanity Group GmbH
- Tilray
- Valcon Medical
For more information about this report visit https://www.researchandmarkets.com/r/dh7q46
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
-
Cannabis2 weeks ago
Silly Nice Announces Launch of New 1G 510 Vape Cartridge and 2G All-In-One Vape in New York Dispensaries This September
-
Cannabis2 weeks ago
Cannabis Cultivation Market – Global Food Additives, Oils, Tinctures, Cannabis Indica, Cannabis Sativa Forecast 2024-2030
-
Cannabis1 week ago
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
-
Cannabis2 weeks ago
Global Hemp Based Food Market Size To Worth USD 4.87 Billion By 2033 | CAGR Of 13.12%
-
Innocan1 week ago
Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options
-
Indivior4 days ago
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder